Saquinavir dosage and administration: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Saquinavir }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INVIRASE (SAQUINAVIR MESYLATE) CAPSULE INVIR..." |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Dosage And Administration== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INVIRASE (SAQUINAVIR MESYLATE) CAPSULE INVIRASE (SAQUINAVIR MESYLATE) TABLET, FILM COATED [GENENTECH, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a | publisher = | date = | accessdate = }}</ref> | INVIRASE must be used in combination with ritonavir because ritonavir significantly inhibits saquinavir's metabolism to provide increased plasma saquinavir levels. | ||
===Recommended Dose=== | |||
*INVIRASE 1000-mg twice daily (5 × 200-mg capsules or 2 × 500-mg tablets) in combination with ritonavir 100-mg twice daily. | |||
*Ritonavir should be taken at the same time as INVIRASE. | |||
*INVIRASE and ritonavir should be taken within 2 hours after a meal. | |||
*No additional ritonavir is recommended when INVIRASE is administered with lopinavir/ritonavir 400/100 mg twice daily. | |||
*Pediatric dose recommendations that are both reliably effective and below thresholds of concern for QT and PR interval prolongation could not be determined. | |||
===Administration for Patients Unable to Swallow Capsules=== | |||
Open the INVIRASE capsules and place the contents into an empty container. Add 15 mL of either sugar syrup or sorbitol syrup (for patients with Type 1 diabetes or glucose intolerance) OR 3 teaspoons of jam to the contents of INVIRASE capsules that are in the container. Stir with a spoon for 30 to 60 seconds. Administer the full amount prepared for each dose. Suspensions should be at room temperature before administering.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INVIRASE (SAQUINAVIR MESYLATE) CAPSULE INVIRASE (SAQUINAVIR MESYLATE) TABLET, FILM COATED [GENENTECH, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a | publisher = | date = | accessdate = }}</ref> | |||
Latest revision as of 17:01, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Dosage And Administration
INVIRASE must be used in combination with ritonavir because ritonavir significantly inhibits saquinavir's metabolism to provide increased plasma saquinavir levels.
Recommended Dose
- INVIRASE 1000-mg twice daily (5 × 200-mg capsules or 2 × 500-mg tablets) in combination with ritonavir 100-mg twice daily.
- Ritonavir should be taken at the same time as INVIRASE.
- INVIRASE and ritonavir should be taken within 2 hours after a meal.
- No additional ritonavir is recommended when INVIRASE is administered with lopinavir/ritonavir 400/100 mg twice daily.
- Pediatric dose recommendations that are both reliably effective and below thresholds of concern for QT and PR interval prolongation could not be determined.
Administration for Patients Unable to Swallow Capsules
Open the INVIRASE capsules and place the contents into an empty container. Add 15 mL of either sugar syrup or sorbitol syrup (for patients with Type 1 diabetes or glucose intolerance) OR 3 teaspoons of jam to the contents of INVIRASE capsules that are in the container. Stir with a spoon for 30 to 60 seconds. Administer the full amount prepared for each dose. Suspensions should be at room temperature before administering.[1]
References
Adapted from the FDA Package Insert.